Literature DB >> 24879786

Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine.

Ioanna Papadatou1, Cristina Piperi2, Krystallenia Alexandraki2, Antonis Kattamis3, Maria Theodoridou1, Vana Spoulou1.   

Abstract

Current guidelines recommend a combined schedule of a 13-valent pneumococcal conjugate vaccine (PCV13) and PPSV23 (23-valent polysaccharide vaccine) for asplenic individuals. We show that PCV13 induces a T-dependent immune response in asplenic individuals with β-thalassemia, but previous PPSV23s affect the memory B-cell response in a dose- and time-dependent manner. Clinical Trials Registration. NCT01846923.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  immunological hyporesponsiveness; immunological memory; memory B cells; pneumococcal vaccine

Mesh：

Substances：

Year:  2014        PMID： 24879786     DOI： 10.1093/cid/ciu409

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

1.  Redirecting reproductive immunology research toward pregnancy as a period of temporary immune tolerance.

Authors:  Norbert Gleicher; Vitaly A Kushnir; David H Barad
Journal:  J Assist Reprod Genet       Date:  2017-02-10       Impact factor: 3.412

Review 2.  Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?

Authors:  Ioanna Papadatou; Vana Spoulou
Journal:  Clin Vaccine Immunol       Date:  2016-05-06

Review 3.  Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance.

Authors:  Chiara Scelfo; Francesco Menzella; Matteo Fontana; Giulia Ghidoni; Carla Galeone; Nicola Cosimo Facciolongo
Journal:  Vaccines (Basel)       Date:  2021-04-22

4.  Recurrent severe invasive pneumococcal disease in an adult with previously unknown hyposplenia.

Authors:  Vibe C Ballegaard; Lone Schejbel; Steen Hoffmann; Bjørn Kantsø; Christian P Fischer
Journal:  BMC Infect Dis       Date:  2015-04-02       Impact factor: 3.090

Review 5.  Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines.

Authors:  Nicola Principi; Susanna Esposito
Journal:  Int J Mol Sci       Date:  2016-12-25       Impact factor: 5.923

Review 6.  Recommended vaccinations for asplenic and hyposplenic adult patients.

Authors:  Paolo Bonanni; Maddalena Grazzini; Giuditta Niccolai; Diana Paolini; Ornella Varone; Alessandro Bartoloni; Filippo Bartalesi; Maria Grazia Santini; Simonetta Baretti; Carlo Bonito; Paola Zini; Maria Teresa Mechi; Fabrizio Niccolini; Lea Magistri; Maria Beatrice Pulci; Sara Boccalini; Angela Bechini
Journal:  Hum Vaccin Immunother       Date:  2017-02       Impact factor: 3.452

Review 7.  The Role of Serotype-Specific Immunological Memory in Pneumococcal Vaccination: Current Knowledge and Future Prospects.

Authors:  Ioanna Papadatou; Irene Tzovara; Paul V Licciardi
Journal:  Vaccines (Basel)       Date:  2019-01-29

8. 

Authors:  Hans-Jürgen Laws; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Maximilian Christopeit; Jane Hecht; Ulrich Heininger; Inken Hilgendorf; Winfried Kern; Kerstin Kling; Guido Kobbe; Wiebe Külper; Thomas Lehrnbecher; Roland Meisel; Arne Simon; Andrew Ullmann; Maike de Wit; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-05       Impact factor: 1.513

9.  The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.

Authors:  Gabrielle Nicole Gaultier; William McCready; Marina Ulanova
Journal:  BMC Immunol       Date:  2019-11-12       Impact factor: 3.615

10.  Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence.

Authors:  Erica Chilson; Daniel A Scott; Beate Schmoele-Thoma; Wendy Watson; Mary M Moran; Raul Isturiz
Journal:  Hum Vaccin Immunother       Date:  2020-06-12       Impact factor: 3.452
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.